Kanta Subbarao

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adultspublié le 2026

Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australiapublié le 2026

Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenzapublié le 2026

PICOBOO: the immunogenicity of COVID-19 booster vaccines in individuals >12 years oldpublié le 2026

SARS-CoV-2 infection patterns and immune responses by fourth-dose COVID-19 vaccination statuspublié le 2026

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trialpublié le 2026

Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Virusespublié le 2026

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59publié le 2026

Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2publié le 2026

AIRBORNE INFECTIOUS SARS-COV-2 IN RECENTLY DIAGNOSED PATIENTS: INSIGHTS FOR HOSPITAL SAFETYpublié le 2026

Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccinationpublié le 2026

Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assayspublié le 2026-08-27

De novo administration of antiviral monoclonal antibodies against SARS-CoV-2 or influenza using mRNA lipid nanoparticlespublié le 2025

Ultraviolet radiation vs air filtration to mitigate virus laden aerosol in an occupied clinical roompublié le 2025

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccinespublié le 2025

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronaviruspublié le 2025

Antibody responses against influenza A decline with successive years of annual influenza vaccinationpublié le 2025

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationpublié le 2025

The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dosepublié le 2025

Contemporary seasonal human coronaviruses display differences in cellular tropism compared to laboratory-adapted reference strainspublié le 2025

Genetic markers of enhanced functional antibody responses to COVID-19 vaccinationpublié le 2025

High-stability, clamp-free soluble Sarbecovirus spike trimers and their potential for pan-Sarbecovirus vaccine development.publié le 2025

Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccinationpublié le 2025

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023publié le 2025

Severe acute respiratory syndrome coronavirus-2 shedding in exhaled material: a systematic reviewpublié le 2025

Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2publié le 2025-10-23

Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infectionpublié le 2024

Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United Statespublié le 2024

The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS-CoV-2 infection in cultured human lung cellspublié le 2024

The Platform Trial I n CO VID-19 Priming and BOO sting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years oldpublié le 2024

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolpublié le 2024

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trialpublié le 2024

Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UKpublié le 2024

Speci fi c and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines - an exploratory sub-study of the BRACE trialpublié le 2024

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years oldpublié le 2024

Human coronavirus OC43 nanobody neutralizes virus and protects mice from infectionpublié le 2024

Modelling the synergy between single-occupancy and PPE in controlling COVID-19 outbreaks on hospital wardspublié le 2024-12-26

Implications of the apparent extinction of B/Yamagata-lineage human influenza virusespublié le 2024-11-16

Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19publié le 2023

Respiratory viruses: New frontiers-a Keystone Symposia reportpublié le 2023

Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatmentpublié le 2023

Virology under the Microscope-a Call for Rational Discoursepublié le 2023

Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion releasepublié le 2023

Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 monthspublié le 2023

The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia publié le 2023

Detection of Influenza in Managed Quarantine in Australia and the Estimated Risk of Importationpublié le 2023

Robust SARS-CoV-2 T cell responses with common TCRab motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cellspublié le 2023

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccinespublié le 2023

Role of the viral polymerase during adaptation of influenza A viruses to new hostspublié le 2023

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infectionpublié le 2023

What HaveWe Learned by Resurrecting the 1918 Influenza Virus?publié le 2023

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantspublié le 2023

Predicting the efficacy of variant-modified COVID-19 vaccine boosterspublié le 2023

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccinepublié le 2023

The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022publié le 2023

Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbiditiespublié le 2023

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterpublié le 2023

Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19 publié le 2023

A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblastspublié le 2023

When to update COVID-19 vaccine compositionpublié le 2023

Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tractpublié le 2023

Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potentialpublié le 2023

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)publié le 2023

Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialpublié le 2023

Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and ?? T cell perturbationspublié le 2023

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022publié le 2023

What influenza activity can we anticipate in 2022?publié le 2022

The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australiapublié le 2022

Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoidspublié le 2022

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Virusespublié le 2022

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cellspublié le 2022

Long-read RNA sequencing identifies polyadenylation elongation and differential transcript usage of host transcripts during SARS-CoV-2 in vitro infectionpublié le 2022

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020publié le 2022

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effectspublié le 2022

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Modelpublié le 2022

Sequential Transmission of Influenza Viruses in Ferrets Does Not Enhance Infectivity and Does Not Predict Transmissibility in Humanspublié le 2022

Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activationpublié le 2022

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2publié le 2022

Comparison of Seroconversion in Children and Adults With Mild COVID-19publié le 2022

Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19publié le 2022

Nonhuman primate models for evaluation of SARS-CoV-2 vaccinespublié le 2022

Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infectionpublié le 2022

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercisepublié le 2022

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Micepublié le 2022

Robust and prototypical immune responses towards COVID-19 BNT162b2 vaccines in Indigenous peoplepublié le 2022

Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?publié le 2022

A new route to vaccines using PROTACspublié le 2022

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccinepublié le 2022

ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsiespublié le 2022

Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial modelpublié le 2022

Temporal differences in culturable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) from the respiratory and gastrointestinal tracts in a patient with moderate coronavirus disease 2019 (COVID-19)publié le 2022

Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infectionpublié le 2022

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2publié le 2022

Preclinical and clinical developments for combination treatment of influenzapublié le 2022